Study: Diabetes Drug May Cut Risk of Alzheimer’s and Parkinson’s …
WEB11 hours ago · A study indicates that diabetes drugs called SGLT2 inhibitors may reduce the risk of dementia and Parkinson’s disease by up to 30%. SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, according to a large study.Results showed a 20% to 30% lower risk for these conditions, though further research is needed for long ...
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in …
WEB3 days ago · References: Kim HK, Biessels GJ, Yu MH, et al. SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes. Neurology. 2024 Oct 22;103(8):e209805. doi:10. ...
FDA Update: Sotagliflozin Approved For Broad HF Treatment
WEBJun 5, 2023 · The U.S. Food and Drug Administration (FDA) on May 26 approved a new drug application submitted by Lexicon Pharmaceuticals, Inc. for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ejection fraction and HF with reduced ejection fraction.
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
WEBJun 29, 2023 · Patients now have an even better chance at survival with the recent FDA approval of Inpefa, the brand name of the drug sotagliflozin. It is the first sodium glucose cotransporter (SGLT) inhibitor that addresses glucose reabsorption in both the kidneys and the small intestine.
SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective …
WEBSep 3, 2024 · The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.
SGLT2 inhibitor empagliflozin is shown to be safe and effective for ...
WEBSep 2, 2024 · The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction...
KDIGO provided recommendations on SGLT2 inhibitors and …
WEBMay 12, 2023 · Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
SGLT2 Inhibitor Use in Stage 5 CKD Cuts Risks for Cardiovascular ...
WEBApr 30, 2024 · Initiating sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy reduces risks for major adverse events even among patients with stage 5 nondialysis-dependent chronic kidney disease (CKD)...
SGLT2 inhibitors in CKD and HFpEF: two new large trials and two …
WEBFeb 1, 2023 · Results from two new trials and two new meta-analyses conclusively demonstrate the cardio-protective and kidney-protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors across the breadth of heart failure and chronic kidney disease populations studied, with absolute benefits convincingly outweighing the …
Applications of SGLT2 inhibitors beyond glycaemic control
WEBApr 26, 2024 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of kidney disease progression in people with or without diabetes as well as the risk of acute kidney injury and...